NEUPOGEN
Biological
Amgen Inc.
Total Payments
$1.0M
Transactions
49
Doctors
26
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $79.18 | 4 | 4 |
| 2022 | $149.49 | 6 | 6 |
| 2021 | $5,551 | 17 | 6 |
| 2020 | $743.78 | 3 | 2 |
| 2019 | $373,998 | 2 | 1 |
| 2018 | $427,779 | 5 | 2 |
| 2017 | $227,462 | 12 | 8 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.0M | 29 | 99.8% |
| Space rental or facility fees (teaching hospital only) | $1,384 | 2 | 0.1% |
| Food and Beverage | $302.39 | 17 | 0.0% |
| Consulting Fee | $195.00 | 1 | 0.0% |
Payments by Type
Research
$1.0M
29 transactions
General
$1,881
20 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Incidence of Hematologic and Non-Hematologic Malignancies, Thrombotic Events, and Autoimmune Disorders in Unrelated Normal Donors Undergoing Bone Marrow Harvest Versus Peripheral Blood Stem Cell Mobilization with Recombinant Human Granulocyte Colony | Amgen Inc. | $742,522 | 0 |
| AMG 900 FIH | Amgen Inc. | $152,986 | 0 |
| Severe Chronic Neutropenia International Registry | Amgen Inc. | $126,000 | 0 |
| Effect Neulasta? (pegfilgrastim) Onpro? Kit-Cancer Care: A Real-World Health SysRetrospective Cohort | Amgen Inc. | $2,737 | 1 |
| PAVES CT Avastin | Amgen Inc. | $2,492 | 1 |
| Prospective Observational Study of Onpro vs SOC. | Amgen Inc. | $2,140 | 4 |
| Incidence of Febrile Neutropenia (FN), Adherence and Compliance to Granulocyte Colony-Stimulating Factor (G-CSF) On-Body Injector (OBI) Versus Other FN Prophylaxis in Patients Receiving Myelosuppressive Chemotherapy: Subgroup Analysis in Breast Cance | Amgen Inc. | $1,718 | 5 |
| A multicenter, prospective, observational study comparing the incidence of febrile neutropenia (FN), adherence and compliance to granulocyte colony-stimulating factor (G-CSF) on-body injector (Neulasta OBI) versus other FN prophylaxis in patients | Amgen Inc. | $1,067 | 5 |
| Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients | Amgen Inc. | $849.90 | 1 |
| Dose delays; Dose Reductions; and RDI among patients receiving regimens w/high risk for FN. | Amgen Inc. | $583.01 | 1 |
| Analysis of hospitalizations in cancer patients with chemotherapy in Medicare; 2012-2015 | Amgen Inc. | $472.20 | 2 |
| Use of short-acting GCSF and risk of FN in elderly population | Amgen Inc. | $271.58 | 1 |
| FN risk reduction with GCSF prophylaxis among breast cancer patients at high FN risk | Amgen Inc. | $42.75 | 1 |
Top Doctors Receiving Payments for NEUPOGEN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Durham, NC | $1.0M | 9 |
| , MD | Hematology | Memphis, TN | $2,737 | 1 |
| , MD | Medical Oncology | Portland, OR | $2,492 | 1 |
| , MD | Medical Oncology | Seattle, WA | $2,343 | 6 |
| , D.O | Hematology & Oncology | Deerfield Beach, FL | $1,568 | 4 |
| , MD | Internal Medicine | Seattle, WA | $984.95 | 3 |
| , M.D | Hematology & Oncology | Durham, NC | $984.95 | 3 |
| , MD | Hematology & Oncology | Denver, CO | $556.96 | 2 |
| , MD | Hematology & Oncology | Philadelphia, PA | $278.85 | 2 |
| , M.D., MSC | Internal Medicine | Winston Salem, NC | $195.00 | 1 |
| , M.D | Specialist | Fountain Valley, CA | $27.19 | 1 |
| , M.D., PH.D | Hematology & Oncology | Renton, WA | $26.14 | 1 |
| , M.D | Hematology & Oncology | Seattle, WA | $26.04 | 1 |
| , ARNP | Family | Lititz, PA | $26.04 | 1 |
| , MD | Medical Oncology | Leesburg, FL | $22.27 | 1 |
| , MD | Anesthesiology | Leesburg, FL | $22.27 | 1 |
| Abdol Mojab | — | Modesto, CA | $22.04 | 1 |
| , MD | Hematology & Oncology | Modesto, CA | $22.04 | 1 |
| Jessica Claro | Nurse Practitioner | New York, NY | $17.32 | 1 |
| , M.D | Hematology & Oncology | New York, NY | $17.32 | 1 |
| Loreta Garretson | Internal Medicine | Murray, KY | $12.55 | 1 |
| , M.D, PH.D | Internal Medicine | Orlando, FL | $10.35 | 1 |
| , MD | Internal Medicine | Orlando, FL | $10.35 | 1 |
| , MD | Internal Medicine | Ann Arbor, MI | $10.35 | 1 |
| , D.O | Anatomic Pathology & Clinical Pathology | Orlando, FL | $10.35 | 1 |
Ad
Manufacturing Companies
- Amgen Inc. $1.0M
- Amneal Pharmaceuticals LLC $228.67
Product Information
- Type Biological
- Total Payments $1.0M
- Total Doctors 26
- Transactions 49
About NEUPOGEN
NEUPOGEN is a biological associated with $1.0M in payments to 26 healthcare providers, recorded across 49 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2017 to 2024. In 2024, $79.18 was paid across 4 transactions to 4 doctors.
The most common payment nature for NEUPOGEN is "Unspecified" ($1.0M, 99.8% of total).
NEUPOGEN is associated with 13 research studies, including "Incidence of Hematologic and Non-Hematologic Malignancies, Thrombotic Events, and Autoimmune Disorders in Unrelated Normal Donors Undergoing Bone Marrow Harvest Versus Peripheral Blood Stem Cell Mobilization with Recombinant Human Granulocyte Colony" ($742,522).